Follow-On Offering

Follow-On Offering


Baird served as co-manager on this transaction


InterMune, Inc. (“Intermune” or the “Company”) (NASDAQ-GS: ITMN) recently completed a follow-on offering of 8,625,000 shares of common stock at a price of $32.75 per share, generating gross proceeds of $282.5 million. The Company intends to use the net proceeds from the offering to fund the commercialization activities in anticipation of the potential commercial launch of Esbriet® (pirfenidone) in the United States and ongoing commercialization in Europe, to fund research and development programs with Esbriet® and other compounds intended to address idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases and for general corporate purposes.

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, the Company is focused on therapies for the treatment of idiopathic pulmonary fibrosis, or IPF, a progressive, irreversible, unpredictable and ultimately fatal lung disease. The Company’s lead product, Esbriet® (pirfenidone), the only medicine approved for IPF in the world, is approved for marketing by InterMune in all 28 member countries of the European Union, or EU and Canada. The Company is headquartered in Brisbane, California.

For additional information about this transaction, please contact:

David Schechner (617) 426-5424
Lance Lange (414) 765-7079
Ryan Mausehund (650) 858-3817
Manish Gupta (414) 765-3802
Satoshi Matsumoto (312) 609-5446
Follow-On Offering
March 2014
InterMune, Inc.
Target Location
North America